LUNGevity is proud to be working with an outstanding team of dedicated scientists and researchers. They are leaders in their fields, with a broad range of expertise.

Members of the Scientific Advisory Board volunteer their time to meet annually in order to advise LUNGevity on the best strategic direction for research investments. Often Board members also generously guide the Foundation on key issues within the early detection and therapeutic arenas.

Charles M. Rudin, MD, PhD

Charles Rudin, MD, PhD

Memorial Sloan Kettering Cancer Center
Cancer Center Deputy Director and Chief, Thoracic Oncology Service

“Every week I see patients with this disease. Every week patients suffer relapses. I have watched too many lung cancer patients die. I am trying to change the outcome for patients with this disease.” — Charles M. Rudin, MD, PhD, Chair of the Scientific Advisory Board


Julie R. Brahmer, MD

Julie R. Brahmer, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Professor of Oncology
Co-Director, Upper Aerodigestive (UAD) Program
Director, Thoracic Oncology Program
Director, Johns Hopkins Kimmel Cancer Center at Bayview

Julie R. Brahmer, MD, is a global thought leader in the emerging field of immunotherapy. Dr. Brahmer is  Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.


Lauren Averett Byers, MD

The University of Texas MD Anderson Cancer Center
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine

Dr. Byers is an associate professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.


David P. Carbone, MD, PhD

David P. Carbone, MD, PhD

The Ohio State University
Wexner Medical Center
Comprehensive Cancer Center

Professor, Division of Medical Oncology
Barbara J. Bonner Chair in Lung Cancer Research
Director of the James Thoracic Oncology Center
Past President, International Association for the Study of Lung Cancer (IASLC)

I think it’s important to try to learn the most we can from patients. EGFR mutations were discovered because we saw a lung cancer patient that had an unusual response to a targeted drug and then we chased it down.” — David P. Carbone, MD, PhD


Suzanne E. Dahlberg, PhD

Suzanne E. Dahlberg, PhD

Boston Children's Hospital 
Institutional Centers for Clinical and Translational Research
Assistant Director of Clinical Trial Biostatistics and Data Management

Suzanne Dahlberg is assistant director of Clinical Trial Biostatistics and Data Management for the Institutional Centers for Clinical and Translational Research at Boston's Children's Hospital as well a a statistician collaborating with the hospital's Divisions of AdolescentYoung Adult Medicine and Pulmonary Medicine.


Maximilian Diehn, MD, PhD

Maximilian Diehn, MD, PhD

Stanford University School of Medicine
CRK Faculty Scholar and Associate Professor
Division Chief of Radiation and Cancer Biology & Vice Chair of Research
Department of Radiation Oncology
Stanford Cancer Institute
Institute for Stem Cell Biology and Regenerative Medicine

Maximilian Diehn is the CRK Faculty Scholar and Associate Professor of Radiation Oncology at Stanford University. He is the Vice Chair of Research of the Department of Radiation Oncology and the Division Chief of Radiation and Cancer Biology.


Jessica S. Donington, MD, MSCR

Jessica S. Donington, MD, MSCR

University of Chicago Medicine 
Professor of Surgery
Chief, Section of Thoracic Surgery

Dr. Donington is Professor and Chief of the Section of General Thoracic Surgery at University of Chicago Medicine.


Steven M. Dubinett, MD

Steven M. Dubinett, MD

David Geffen School of Medicine at UCLA
Dean
Associate Vice Chancellor for Research
Distinguished Professor of Medicine, Pharmacology and Pathology
Director, Clinical and Translational Science Institute 

“We have lacked the imagination to adequately fund research in lung cancer.” — Steven M. Dubinett, MD


Patrick Forde, MD (MB, BCH)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Associate Professor of Oncology
Director of the Thoracic Cancer Clinical Research Program

Dr. Forde has led the development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies.


Edward W. Gabrielson, MD

Edward W. Gabrielson, MD

Johns Hopkins University School of Medicine
Professor of Pathology and Oncology

Dr. Edward W. Gabrielson is a professor of pathology and oncology at the Johns Hopkins University School of Medicine.


Edward B. Garon, MD

Edward B. Garon, MD

Jonsson Comprehensive Cancer Center at UCLA
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Professor of Medicine, Division of Hematology-Oncology

Edward Garon, MD, is the director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA and professor of Medicine at David Geffens School of Medicine at UCLA.


Dr. John V. Heymach

John V. Heymach, MD, PhD

The University of Texas MD Anderson Cancer Center
Professor and Chairman, Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine 

Dr. John V. Heymach is the Chairman of Thoracic/Head and Neck Medical Oncology, the Chief of Thoracic Medical Oncology, and an Associate Professor in the Departments of Thoracic Head and Neck Medical Oncology and Cancer Biology at The University of Texas MD Anderson Cancer Center.


Robert L. Keith, MD

Robert L. Keith, MD

University of Colorado, Denver
Professor of Medicine and Cancer Biology
Rocky Mountain Regional VAMC
Associate Chief of Staff - Research

“We need resources to be put towards lung cancer in a way that matches the burden in the community… It is critical to raise public awareness and put the money where the patients are.”  — Robert L. Keith, MD


Benjamin P. Levy, MD

Benjamin P. Levy, MD

Johns Hopkins School of Medicine:
Associate Professor
Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC:
Clinical Director

Dr. Benjamin Levy is associate professor at the Johns Hopkins School of Medicine and clinical director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington, DC.


Christine Lovely, MD, PhD

Christine M. Lovly, MD, PhD

Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center

Associate Professor of Medicine, Division of Hematology-Oncology
Ingram Associate Professor of Cancer Research
Co-Leader, Translational Research and Interventional Oncology Program
Section Chief, Basic and Translational Research, Division of Hematology-Oncology

Dr. Lovly, a former LUNGevity Career Development Awardee, is a physician-scientist who splits her time between clinical care and laboratory research.


Pierre P. Massion, MD

Pierre P. Massion, MD

Deceased
Vanderbilt-Ingram Cancer Center
Cornelius Vanderbilt Endowed Chair in Medicine
Professor of Medicine and Cancer Biology
Director, Thoracic Program

Dr. Pierre Massion is a world-renowned and highly-published expert in the early detection of lung cancer.


Drew Moghanaki, MD, MPH

Drew Moghanaki, MD, MPH

UCLA Department of Radiation Oncology
Stanley Lezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research
Professor and Chief of Thoracic Oncology
VA Greater Los Angeles Healthcare System

Dr. Drew Moghanaki is Professor and Chief of Thoracic Oncology in the UCLA Department of Radiation Oncology. He holds a joint appointment at the VA Greater Los Angeles Healthcare System, where he directs patient care and research for veterans with lung cancer.


Paul K. Paik, MD

Paul K. Paik, MD

Memorial Sloan Kettering Cancer Center
Associate Attending Physician
Clinical Director, Thoracic Oncology Service

Paul Paik is a medical oncologist at Memorial Sloan Kettering Cancer Center who specializes in the treatment of lung cancers.


Lawrence H. Schwartz, MD

Lawrence H. Schwartz, MD

Memorial Sloan Kettering Cancer Center
Chair, Department of Radiology

Working together, we can improve imaging techniques to make a tremendous impact on lung cancer in terms of figuring out how to diagnose it better, how to treat patients and how we monitor lung cancer treatments.” – Lawrence H. Schwartz, MD


Lecia V. Sequist, MD, MPH

Lecia V. Sequist, MD, MPH

Massachusetts General Cancer Center
Program Director, Cancer Early Detection and Diagnostics Clinic
Harvard Medical School
Landry Family Professor of Medicine

Research allows me to give hope to my patients and show them what might be possible.” — Lecia V. Sequist, MD, MPH


Alice T. Shaw, MD, PhD

Alice T. Shaw, MD, PhD

Novartis Institutes for BioMedical Research
Vice President, Global Head of Translational Clinical Oncology

Dr. Shaw is the vice president, Global Head of Translational Clinical Oncology, at Novartis Institutes for BioMedical Research.


Steven J. Skates, PhD

Steven J. Skates, PhD

Harvard Medical School and Massachusetts General Hospital
Associate Professor

“My hope is that all my years of study and training ultimately have an effect on patients’ lives. In the end, new discoveries are really the stepping stones to helping patients.” — Steven J. Skates, PhD


Avrum Spira, MD, MSc

Avrum Spira, MD, MSc

Johnson & Johnson
Global Head, Lung Cancer Initiative
Boston University
Professor of Medicine, Pathology & Bioinformatics

“What we can do now scientifically is unprecedented and it’s going to get even better over the next five years.” — Avrum Spira, MD, MSc


Dr. Brendon Stiles

Brendon Stiles, MD

Montefiore Health System, Bronx, NY
Chief of Thoracic Surgery and Surgical Oncology
Albert Einstein Cancer Center
Associate Director of Surgical Oncology

Dr. Stiles has clinical expertise in lung and esophageal cancer and also leads a comprehensive translational and clinical lung cancer research program.


LUNGevity Scientific Advisory Board member Anil Vachani, MD

Anil Vachani, MD

University of Pennsylvania
Associate Professor of Medicine, Pulmonary, Allergy, and Critical Care Division

Dr. Vachani is a pulmonologist and physician-scientist at Penn Medicine and the Philadelphia VA Medical Center.